LivaNova plc (NASDAQ: LIVN) reported Q4 EPS of $0.71, $0.05 better than the analyst estimate of $0.66. Revenue for the quarter came in at $269.6 million versus the consensus estimate of $268.83 million.

"Sales in all product categories and regions improved sequentially over the third quarter of 2020," said Damien McDonald, Chief Executive Officer of LivaNova. "We start 2021 with three clear objectives: execute on our core growth drivers, achieve the milestones for our pipeline priorities, and continue to execute on initiatives to improve profitability and cash generation. These fundamental objectives, combined with our expectation for declining COVID-19 infection rates, make us optimistic that our 2021 results will improve over the course of the year. We believe our efforts will enable us to most effectively serve our patients and position the company to achieve long-term success."

GUIDANCE:

LivaNova plc sees FY2021 EPS of $1.40-$1.90, versus the consensus of $1.98.

While continued COVID-related uncertainty is anticipated in 2021, sales levels are expected to return to more normalized levels in the second half of the year. As a result, LivaNova expects worldwide net sales from continuing operations for full-year 2021 to grow between 8 and 13 percent on a constant-currency basis. Adjusted diluted earnings per share from continuing operations for 2021 are expected to be in the range of $1.40 to $1.90. In 2021, the Company estimates that adjusted free cash flow, excluding extraordinary items, will be in the range of $30 to $50 million.

For earnings history and earnings-related data on LivaNova plc (LIVN) click here.